Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 2.5.1.61 - hydroxymethylbilane synthase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Adenocarcinoma
Biochemical basis of 5-aminolaevulinic acid-induced protoporphyrin IX accumulation: a study in patients with (pre)malignant lesions of the oesophagus.
Delta-aminolaevulinic acid-induced photodynamic therapy inhibits protoporphyrin IX biosynthesis and reduces subsequent treatment efficacy in vitro.
Effect of estrogenic perturbations on delta-aminolevulinic acid-induced porphobilinogen deaminase and protoporphyrin IX levels in rat Harderian glands, liver, and R3230AC tumors.
Anemia
Effects of recombinant human erythropoietin on porphyrin metabolism in uremic patients on hemodialysis.
Erythrocyte uroporphyrinogen synthase activity as a possible diagnostic aid in the diagnosis of lymphoproliferative diseases.
Heme biosynthesis in uremic patients on CAPD or hemodialysis.
Heme synthesis in anemia of the uremic state.
Red cell uroporphyrinogen I synthetase in acute intermittent porphyria.
Whole Exome Sequencing Identified a Novel Heterozygous Mutation in HMBS Gene in a Chinese Patient With Acute Intermittent Porphyria With Rare Type of Mild Anemia.
Arthritis, Rheumatoid
[New aspects in the pathogenesis of anemia in chronic polyarthritis]
Astrocytoma
Sodium butyrate increases the effect of the photodynamic therapy: a mechanism that involves modulation of gene expression and differentiation in astrocytoma cells.
Ataxia
Homozygous hydroxymethylbilane synthase knock-in mice provide pathogenic insights into the severe neurological impairments present in human homozygous dominant acute intermittent porphyria.
Atrial Fibrillation
Identification of optimal reference genes for transcriptomic analyses in normal and diseased human heart.
Autoimmune Diseases
Quantitative real-time RT-PCR using hybridization probes and imported standard curves for cytokine gene expression analysis.
Brain Diseases
A novel heterozygous mutation in the HMBS gene in a patient with acute intermittent porphyria and posterior reversible encephalopathy syndrome.
Acute intermittent porphyria-related leukoencephalopathy.
Brain Ischemia
Decreased beta-actin mRNA expression in hyperglycemic focal cerebral ischemia in the rat.
Breast Neoplasms
DC-SCRIPT: nuclear receptor modulation and prognostic significance in primary breast cancer.
Effects of Silencing Heme Biosynthesis Enzymes on 5-Aminolevulinic Acid-mediated Protoporphyrin IX Fluorescence and Photodynamic Therapy.
Identification of endogenous reference genes for qRT-PCR analysis in normal matched breast tumor tissues.
Relative levels of let-7a, miR-17, miR-27b, miR-125a, miR-125b and miR-206 as potential molecular markers to evaluate grade, receptor status and molecular type in breast cancer.
Carcinogenesis
Nuclear distribution of porphobilinogen deaminase (PBGD) in glioma cells: a regulatory role in cancer transformation?
Carcinoma
Gene expression studies in prostate cancer tissue: which reference gene should be selected for normalization?
Identification and Validation of Housekeeping Genes for Gene Expression Analysis of Cancer Stem Cells.
Identification of reference genes for qRT-PCR in human lung squamous-cell carcinoma by RNA-Seq.
Phenotypic mismatch repair hMSH2 and hMLH1 gene expression profiles in primary non-small cell lung carcinomas.
Reference gene selection for head and neck squamous cell carcinoma gene expression studies.
Carcinoma, Hepatocellular
A Pharmacological Chaperone Therapy for Acute Intermittent Porphyria.
Evaluation of potential reference genes for qRT-PCR studies in human hepatoma cell lines treated with TNF-?.
Carcinoma, Squamous Cell
Reference gene selection for head and neck squamous cell carcinoma gene expression studies.
Cholecystitis
Acute intermittent porphyria caused by novel mutation in HMBS gene, misdiagnosed as cholecystitis.
Colonic Neoplasms
Distinct genomic and epigenomic features demarcate hypomethylated blocks in colon cancer.
Communicable Diseases
Increased porphobilinogen deaminase activity in patients with malignant lymphoproliferative diseases. A helpful diagnostic test.
Coproporphyria, Hereditary
A next-generation-sequencing panel for mutational analysis of dominant acute hepatic porphyrias.
International Porphyria Molecular Diagnostic Collaborative: an evidence-based database of verified pathogenic and benign variants for the porphyrias.
Seven Novel Mutations in Bulgarian Patients with Acute Hepatic Porphyrias (AHP).
COVID-19
Maintaining human milk bank services throughout the COVID-19 pandemic: A global response.
Dengue
Endogenous gene selection for relative quantification PCR and IL6 transcript levels in the PBMC's of severe and non-severe dengue cases.
Dermatitis, Phototoxic
Effect of delta-aminolevulinic acid on protoporphyrin IX accumulation in tumor cells transfected with plasmids containing porphobilinogen deaminase DNA.
Epilepsy
The challenge of managing comorbidities: a case report of primary Sjogren's syndrome in a patient with acute intermittent porphyria.
Fanconi Anemia
In vitro CFU-E and BFU-E responses to androgen in bone marrow from children with primary hypoproliferative anaemia: a possible therapeutic assay.
Genetic Diseases, Inborn
Acute intermittent porphyria: diagnostic conundrums.
Biochemical characterization of porphobilinogen deaminase-deficient mice during phenobarbital induction of heme synthesis and the effect of enzyme replacement.
Decreased nocturnal plasma melatonin levels in patients with recurrent acute intermittent porphyria attacks.
High prevalence of and potential mechanisms for chronic kidney disease in patients with acute intermittent porphyria.
Kidney damage in acute intermittent porphyria.
[Molecular genetic study of acute intermittent porphyria in Russia: mutation analysis and functional polymorphism search in porphobilinogen deaminase gene]
Glioma
A porphobilinogen deaminase (PBGD) Ran-binding protein interaction is implicated in nuclear trafficking of PBGD in differentiating glioma cells.
Nuclear distribution of porphobilinogen deaminase (PBGD) in glioma cells: a regulatory role in cancer transformation?
Selection of suitable reference genes for expression analysis in human glioma using RT-qPCR.
TCGA mRNA Expression Analysis of the Heme Biosynthesis Pathway in Diffusely Infiltrating Gliomas: A Comparison of Typically 5-ALA Fluorescent and Non-Fluorescent Gliomas.
Heart Failure
Identification of optimal reference genes for transcriptomic analyses in normal and diseased human heart.
Hemochromatosis
Alginate microencapsulated human hepatocytes for the treatment of acute liver failure in children.
Hepatitis
Erythrocyte porphobilinogen deaminase activity in liver disease.
Hepatitis, Chronic
Erythrocyte porphobilinogen deaminase activity in liver disease.
Hodgkin Disease
Porphobilinogen deaminase activity in malignant proliferative disorders of the lymphatic system and bone marrow.
hydroxymethylbilane synthase deficiency
Acute intermittent porphyria: prevalence of mutations in the porphobilinogen deaminase gene in blood donors in France.
Anesthesia in a child with homozygous porphobilinogen deaminase deficiency: a severe form of acute intermittent porphyria.
Characterization of the porphobilinogen deaminase deficiency in acute intermittent porphyria. Immunologic evidence for heterogeneity of the genetic defect.
Glucose metabolism during fasting is altered in experimental porphobilinogen deaminase deficiency.
High prevalence of and potential mechanisms for chronic kidney disease in patients with acute intermittent porphyria.
Homozygous acute intermittent porphyria: compound heterozygosity for adjacent base transitions in the same codon of the porphobilinogen deaminase gene.
Host Porphobilinogen Deaminase Deficiency Confers Malaria Resistance in Plasmodium chabaudi but Not in Plasmodium berghei or Plasmodium falciparum During Intraerythrocytic Growth.
Mitochondrial energetic defects in muscle and brain of a Hmbs-/- mouse model of acute intermittent porphyria.
Molecular forms of porphobilinogen deaminase in acute intermittent porphyria. A study by Western immunoblotting.
Murine models of the human porphyrias: Contributions toward understanding disease pathogenesis and the development of new therapies.
PORPHOBILINOGEN DEAMINASE deficiency alters vegetative and reproductive development and causes lesions in Arabidopsis.
Porphobilinogen deaminase deficiency in mice causes a neuropathy resembling that of human hepatic porphyria.
Severe hydroxymethylbilane synthase deficiency causes depression-like behavior and mitochondrial dysfunction in a mouse model of homozygous dominant acute intermittent porphyria.
Studies in porphyria. IV. Expression of the gene defect of acute intermittent porphyria in cultured human skin fibroblasts and amniotic cells: prenatal diagnosis of the porphyric trait.
Tissue-specific expression of porphobilinogen deaminase. Two isoenzymes from a single gene.
Variegate porphyria with coexistent decrease in porphobilinogen deaminase activity.
Hypertension
Acute intermittent porphyria: A case report
Hypertension, Pulmonary
Identification of reliable reference genes for quantitative real-time PCR in lung and heart of pulmonary hypertensive chickens.
Hypokalemia
Acute intermittent porphyria: A case report
Hyponatremia
Acute intermittent porphyria: A case report
Ichthyosis Vulgaris
A rare case of acute intermittent porphyria with ichthyosis vulgaris in a young boy.
Infections
Elevated hepatic lipid and interferon stimulated gene expression in HCV GT3 patients relative to non-alcoholic steatohepatitis.
Selection and validation of suitable reference genes for qPCR gene expression analysis in goats and sheep under Peste des petits ruminants virus (PPRV), lineage IV infection.
Systematic selection of housekeeping genes for gene expression normalization in chicken embryo fibroblasts infected with Newcastle disease virus.
Jaundice, Chronic Idiopathic
Porphobilinogen deaminase and the synthesis of porphyrin isomers in the Dubin-Johnson syndrome.
Kidney Failure, Chronic
Determination of erythrocyte uroporphyrinogen I synthetase activity in chronic renal failure.
Leukemia
Examination of Stability of Bone Marrow Blood RNA in the PAXgene Tube.
Porphobilinogen deaminase activity in malignant proliferative disorders of the lymphatic system and bone marrow.
PORPHOBILINOGEN DEAMINASE AND ADENOSINE DEAMINASE ACTIVITY AS A POSSIBLE DIAGNOSTIC AID IN LYMPHATIC LEUKEMIAS.
Leukemia, Erythroblastic, Acute
Porphobilinogen deaminase is unstable in the absence of its substrate.
Regional gene assignment of human porphobilinogen deaminase and esterase A4 to chromosome 11q23 leads to 11qter.
Leukemia, Lymphocytic, Chronic, B-Cell
Increased porphobilinogen deaminase activity in patients with malignant lymphoproliferative diseases. A helpful diagnostic test.
Leukemia, Lymphoid
Porphobilinogen deaminase activity in malignant proliferative disorders of the lymphatic system and bone marrow.
Leukoencephalopathies
Acute intermittent porphyria-related leukoencephalopathy.
Expanding the clinical and radiological phenotypes of leukoencephalopathy due to biallelic HMBS mutations.
Lichen Sclerosus et Atrophicus
Lichen sclerosus et atrophicus-like skin lesions in a patient carrying a novel hydroxymethylbilane synthase mutation.
Liver Cirrhosis
Erythrocyte porphobilinogen deaminase activity in liver disease.
Liver Diseases
Erythrocyte porphobilinogen deaminase activity in liver disease.
Erythrocyte porphobilinogen deaminase activity in liver diseases and proliferative diseases of the haemopoietic system and lymph nodes.
Liver Neoplasms
Biallelic inactivation of protoporphyrinogen oxidase and hydroxymethylbilane synthase is associated with liver cancer in acute porphyrias.
Emerging therapies for acute intermittent porphyria.
Erythrocyte porphobilinogen deaminase activity and primary liver cancer.
Validation of putative reference genes for gene expression studies in human hepatocellular carcinoma using real-time quantitative RT-PCR.
Lymphoma
Increased porphobilinogen deaminase activity in patients with malignant lymphoproliferative diseases. A helpful diagnostic test.
Lymphocyte urosynthase in non-Hodgkin's lymphoma. An indicator of disease extensiveness.
[Lymphocyte uroporphyrinogen synthase in the diagnosis of lymphoma and its follow-up]
Lymphoma, Non-Hodgkin
Lymphocyte urosynthase in non-Hodgkin's lymphoma. An indicator of disease extensiveness.
Malaria
Host Porphobilinogen Deaminase Deficiency Confers Malaria Resistance in Plasmodium chabaudi but Not in Plasmodium berghei or Plasmodium falciparum During Intraerythrocytic Growth.
Malnutrition
Influence of protein calorie malnutrition and fasting on the activities of delta-aminolevulinic acid dehydratase and porphobilinogen deaminase in rats.
Melanoma
Reproducibility of detection of tyrosinase and MART-1 transcripts in the peripheral blood of melanoma patients: a quality control study using real-time quantitative RT-PCR.
Melanoma, Experimental
Differentiation-dependent photodynamic therapy regulated by porphobilinogen deaminase in B16 melanoma.
Metabolic Diseases
CRIM-positive mutations of acute intermittent porphyria in Finland.
Diagnosis and Treatment of Acute Intermittent Porphyria.
Dysregulation of homocysteine homeostasis in acute intermittent porphyria patients receiving heme arginate or givosiran.
Emerging therapies for acute intermittent porphyria.
Helper-dependent adenoviral liver gene therapy protects against induced attacks and corrects protein folding stress in acute intermittent porphyria mice.
High penetrance of acute intermittent porphyria in a Spanish founder mutation population and CYP2D6 genotype as a susceptibility factor.
Mitochondrial energetic defects in muscle and brain of a Hmbs-/- mouse model of acute intermittent porphyria.
Neurological manifestations of acute intermittent porphyria.
Nine mutations including three novel mutations among Russian patients with acute intermittent porphyria.
Multiple Sclerosis
Quantitative real-time RT-PCR using hybridization probes and imported standard curves for cytokine gene expression analysis.
Neoplasm Metastasis
Activity of porphobilinogen deaminase in peripheral blood mononuclear cells of patients with metastatic cancer.
Neoplasm, Residual
Examination of Stability of Bone Marrow Blood RNA in the PAXgene Tube.
Neoplasms
A porphobilinogen deaminase (PBGD) Ran-binding protein interaction is implicated in nuclear trafficking of PBGD in differentiating glioma cells.
A regulatory role for porphobilinogen deaminase (PBGD) in delta-aminolaevulinic acid (delta-ALA)-induced photosensitization?
Activity of porphobilinogen deaminase in peripheral blood mononuclear cells of patients with metastatic cancer.
Analysis of the balance between proliferation and apoptosis of cultured vascular smooth muscle cells for tissue-engineering applications.
Biallelic inactivation of protoporphyrinogen oxidase and hydroxymethylbilane synthase is associated with liver cancer in acute porphyrias.
DC-SCRIPT: nuclear receptor modulation and prognostic significance in primary breast cancer.
Effect of delta-aminolevulinic acid on protoporphyrin IX accumulation in tumor cells transfected with plasmids containing porphobilinogen deaminase DNA.
Effect of estrogenic perturbations on delta-aminolevulinic acid-induced porphobilinogen deaminase and protoporphyrin IX levels in rat Harderian glands, liver, and R3230AC tumors.
Erythrocyte porphobilinogen deaminase activity and primary liver cancer.
Erythrocyte uroporphyrinogen I synthase in rats treated with the hepatic carcinogen diethylnitrosamine.
Erythrocyte uroporphyrinogen synthase activity as a possible diagnostic aid in the diagnosis of lymphoproliferative diseases.
Evaluation of potential reference genes for qRT-PCR studies in human hepatoma cell lines treated with TNF-?.
Identification and Validation of Housekeeping Genes for Gene Expression Analysis of Cancer Stem Cells.
Increased porphobilinogen deaminase activity in patients with malignant lymphoproliferative diseases. A helpful diagnostic test.
Metabolic changes in the heme pathway driven by cyclophosphamide treatment in mice.
Nuclear distribution of porphobilinogen deaminase (PBGD) in glioma cells: a regulatory role in cancer transformation?
Quantitative cytokine gene expression in human tonsils at excision and during histoculture assessed by standardized and calibrated real-time PCR and novel data processing.
Reference gene selection for head and neck squamous cell carcinoma gene expression studies.
Sex comparison of heme pathway in rats bearing hepatic tumors.
Validation of putative reference genes for gene expression studies in human hepatocellular carcinoma using real-time quantitative RT-PCR.
Nervous System Diseases
[Acute intermittent porphyria in the puerperium].
Neuroblastoma
Identification and characterization of human LL5A gene and mouse Ll5a gene in silico.
Neurologic Manifestations
Acute intermittent porphyria: studies of the severe homozygous dominant disease provides insights into the neurologic attacks in acute porphyrias.
Obesity
Heme Biosynthetic Pathway is Functionally Linked to Adipogenesis via Mitochondrial Respiratory Activity.
Pelger-Huet Anomaly
Impaired heme synthesis in a family with Pelger-Huët anomaly, recurrent abdominal pain attacks and impaired neutrophil motility in vitro.
Perinatal Death
Breast milk donation after neonatal death in Australia: a report.
Peste-des-Petits-Ruminants
Selection and validation of suitable reference genes for qPCR gene expression analysis in goats and sheep under Peste des petits ruminants virus (PPRV), lineage IV infection.
Photosensitivity Disorders
A regulatory role for porphobilinogen deaminase (PBGD) in delta-aminolaevulinic acid (delta-ALA)-induced photosensitization?
Delta-aminolaevulinic acid-induced photodynamic therapy inhibits protoporphyrin IX biosynthesis and reduces subsequent treatment efficacy in vitro.
Plasmacytoma
Porphobilinogen deaminase activity in malignant proliferative disorders of the lymphatic system and bone marrow.
Porphyria Cutanea Tarda
Erythrocyte porphobilinogen deaminase activity in porphyria cutanea tarda.
Studies on erythrocyte porphobilinogen deaminase and uroporphyrinogen cosynthetase in porphyria cutanea tarda.
The activity of erythrocyte porphobilinogen deaminase in familial and sporadic forms of porphyria cutanea tarda.
Porphyria, Acute Intermittent
"Glucose effect" and rate limiting function of uroporphyrinogen synthase on porphyrin metabolism in hepatocyte culture: relationship with human acute hepatic porphyrias.
A large deletion on chromosome 11 in acute intermittent porphyria.
A microassay for uroporphyrinogen I synthase, one of three abnormal enzyme activities in acute intermittent porphyria, and its application to the study of the genetics of this disease.
A modified spectrophotometric assay for porphobilinogen deaminase: its application in the detection of both carriers and patients with acute intermittent porphyria.
A new mutation within the porphobilinogen deaminase gene leading to a truncated protein as a cause of acute intermittent porphyria in an extended Indian family.
A next-generation-sequencing panel for mutational analysis of dominant acute hepatic porphyrias.
A novel 12-base pair deletion mutation in exon 15 of the porphobilinogen deaminase gene in a Taiwanese patient with acute intermittent porphyria.
A novel 19-bp deletion of exon 15 in the HMBS gene causing acute intermittent porphyria associating with rhabdomyolysis during an acute attack.
A novel 55-basepair deletion of hydroxymethylbilane synthase gene found in a Chinese patient with acute intermittent porphyria and her family: A case report.
A novel G168X mutation and a recurrent 730-731delCT mutation of the porphobilinogen deaminase gene in Japanese patients with acute intermittent porphyria.
A novel heterozygous mutation in the HMBS gene in a patient with acute intermittent porphyria and posterior reversible encephalopathy syndrome.
A novel mutation in a family with non-erythroid variant form of acute intermittent porphyria.
A novel mutation in the porphobilinogen deaminase gene in an extended Chinese family with acute intermittent porphyria.
A Pharmacological Chaperone Therapy for Acute Intermittent Porphyria.
A point mutation G----A in exon 12 of the porphobilinogen deaminase gene results in exon skipping and is responsible for acute intermittent porphyria.
A point mutation, C to T, in exon 8 of the porphobilinogen deaminase gene in a Japanese family with acute intermittent porphyria.
A rare case of acute intermittent porphyria with ichthyosis vulgaris in a young boy.
A splicing mutation in the hydroxymethylbilane synthase gene in a Japanese family with acute intermittent porphyria.
A spot test for uroporphyrinogen I synthase, the enzyme that is deficient in intermittent acute porphyria.
AAV8-mediated Gene Therapy Prevents Induced Biochemical Attacks of Acute Intermittent Porphyria and Improves Neuromotor Function.
Abnormal thyroid function and hypercholesterolemia in a case of acute intermittent porphyria.
Acute intermittent porphyria and mental illness--a family study.
Acute intermittent porphyria and uroporphyrinogen I synthase. Biochemical study of a family.
Acute intermittent porphyria as a cause of respiratory failure: case report.
Acute intermittent porphyria caused by a C----T mutation that produces a stop codon in the porphobilinogen deaminase gene.
Acute intermittent porphyria caused by a G to C mutation in exon 12 of the porphobilinogen deaminase gene that results in exon skipping.
Acute intermittent porphyria caused by a single base insertion of C in exon 15 of the porphobilinogen deaminase gene that results in a frame shift and premature stopping of translation.
Acute intermittent porphyria caused by an arginine to histidine substitution (R26H) in the cofactor-binding cleft of porphobilinogen deaminase.
Acute intermittent porphyria caused by defective splicing of porphobilinogen deaminase RNA: a synonymous codon mutation at -22 bp from the 5' splice site causes skipping of exon 3.
Acute intermittent porphyria caused by novel mutation in HMBS gene, misdiagnosed as cholecystitis.
Acute Intermittent Porphyria Causes Hepatic Mitochondrial Energetic Failure In A Mouse Model.
Acute Intermittent Porphyria in a Man with Dual Enzyme Deficiencies.
Acute intermittent porphyria in Argentina: an update.
Acute intermittent porphyria in Finland: 19 mutations in the porphobilinogen deaminase gene.
Acute intermittent porphyria in Sweden. Molecular, functional and clinical consequences of some new mutations found in the porphobilinogen deaminase gene.
Acute intermittent porphyria in The Netherlands. Heterogeneity of the enzyme porphobilinogen deaminase.
Acute intermittent porphyria in two patients on anticonvulsant therapy and with normal erythrocyte porphobilinogen deaminase activity.
Acute Intermittent Porphyria Presenting with Posterior Reversible Encephalopathy Syndrome: A Rare Cause of Abdominal Pain and Seizures.
Acute intermittent porphyria with transient cortical blindness.
Acute intermittent porphyria--impact of mutations found in the hydroxymethylbilane synthase gene on biochemical and enzymatic protein properties.
Acute intermittent porphyria-related leukoencephalopathy.
Acute intermittent porphyria: A case report
Acute intermittent porphyria: a single-base deletion and a nonsense mutation in the human hydroxymethylbilane synthase gene, predicting truncations of the enzyme polypeptide.
Acute intermittent porphyria: a test of clinical acumen.
Acute intermittent porphyria: alternative splicing of hydroxymethylbilane synthase mRNA excludes exons 3 and 12.
Acute Intermittent Porphyria: An Overview of Therapy Developments and Future Perspectives Focusing on Stabilisation of HMBS and Proteostasis Regulators.
Acute intermittent porphyria: characterization of a novel mutation in the structural gene for porphobilinogen deaminase. Demonstration of noncatalytic enzyme intermediates stabilized by bound substrate.
Acute intermittent porphyria: characterization of two novel mutations in the porphobilinogen deaminase gene, one amino acid deletion (453-455delAGC) and one splicing aceptor site mutation (IVS8-1G>T).
Acute intermittent porphyria: clinicopathologic correlation. Report of a case and review of the literature.
Acute intermittent porphyria: diagnostic conundrums.
Acute intermittent porphyria: expression of mutant and wild-type porphobilinogen deaminase in COS-1 cells.
Acute intermittent porphyria: focus on possible mechanisms of acute and chronic manifestations.
Acute intermittent porphyria: heterogeneity of mutations in the hydroxymethylbilane synthase gene in Italy.
Acute intermittent porphyria: identification and expression of exonic mutations in the hydroxymethylbilane synthase gene. An initiation codon missense mutation in the housekeeping transcript causes "variant acute intermittent porphyria" with normal expression of the erythroid-specific enzyme.
Acute intermittent porphyria: novel missense mutations in the human hydroxymethylbilane synthase gene.
Acute intermittent porphyria: pathophysiology and treatment.
Acute Intermittent Porphyria: Predicted Pathogenicity of HMBS Variants Indicates Extremely Low Penetrance of the Autosomal Dominant Disease.
Acute intermittent porphyria: prevalence of mutations in the porphobilinogen deaminase gene in blood donors in France.
Acute intermittent porphyria: studies of the severe homozygous dominant disease provides insights into the neurologic attacks in acute porphyrias.
Acute intermittent porphyria: the in vitro expression of mutant hydroxymethylbilane synthase.
Acute intermittent porphyria: vector optimization for gene therapy.
Acute porphyrias in the Argentinean population: a review.
Adenoviral-mediated expression of porphobilinogen deaminase in liver restores the metabolic defect in a mouse model of acute intermittent porphyria.
Adrenal hormonal imbalance in acute intermittent porphyria patients: results of a case control study.
An autopsy case of acute porphyria with a decrease of both uroporphyrinogen I synthetase and ferrochelatase activities.
An Inducible Promoter Responsive to Different Porphyrinogenic Stimuli Improves Gene Therapy Vectors for Acute Intermittent Porphyria.
An unusual cause of syndrome of inappropriate antidiuretic hormone secretion.
An update of clinical management of acute intermittent porphyria.
Ancestral founder of mutation W283X in the porphobilinogen deaminase gene among acute intermittent porphyria patients.
Anesthesia in a child with homozygous porphobilinogen deaminase deficiency: a severe form of acute intermittent porphyria.
Assay for erythrocyte uroporphyrinogen I synthase activity, with porphobilinogen as substrate.
Biallelic inactivation of protoporphyrinogen oxidase and hydroxymethylbilane synthase is associated with liver cancer in acute porphyrias.
Biochemical and hematological analysis in acute intermittent porphyria (AIP): a case report.
Biochemical characterization of porphobilinogen deaminase-deficient mice during phenobarbital induction of heme synthesis and the effect of enzyme replacement.
Biochemical differentiation of the porphyrias.
Bioengineered PBGD variant improves the therapeutic index of gene therapy vectors for acute intermittent porphyria.
Carbamazepine-induced non-hereditary acute porphyria.
Characterization of the hepatic transcriptome following phenobarbital induction in mice with AIP.
Characterization of the porphobilinogen deaminase deficiency in acute intermittent porphyria. Immunologic evidence for heterogeneity of the genetic defect.
Characterization of two isoalleles and three mutations in both isoforms of purified recombinant human porphobilinogen deaminase.
Characterization of two missense variants in the hydroxymethylbilane synthase gene in the Israeli population, which differ in their associations with acute intermittent porphyria.
Chester porphyria: biochemical studies of a new form of acute porphyria.
Circulating fluorocytes at the first attack of acute intermittent porphyria: A missing link in the pathogenesis.
Clinical and biochemical characteristics and genotype-phenotype correlation in 143 Finnish and Russian patients with acute intermittent porphyria.
Comparison of complementary and genomic DNA sequencing for the detection of mutations in the HMBS gene in British patients with acute intermittent porphyria: identification of 25 novel mutations.
Comprehensive analysis of the tryptophan metabolome in urine of patients with acute intermittent porphyria.
Conformational stability and activity analysis of two hydroxymethylbilane synthase mutants, K132N and V215E, with different phenotypic association with acute intermittent porphyria.
Correction of the biochemical defect in porphobilinogen deaminase deficient cells by non-viral gene delivery.
Correlation between biochemical findings, structural and enzymatic abnormalities in mutated HMBS identified in six Israeli families with acute intermittent porphyria.
CRIM-positive mutations of acute intermittent porphyria in Finland.
Danazol administration to females with menses-associated exacerbations of acute intermittent porphyria.
De Novo mutation found in the porphobilinogen deaminase gene in Slovak acute intermittent porphyria patient: molecular biochemical study.
Decreased nocturnal plasma melatonin levels in patients with recurrent acute intermittent porphyria attacks.
Decreased red cell uroporphyrinogen I synthetase activity in intermittent acute porphyria.
Demystification of Chester porphyria: a nonsense mutation in the Porphobilinogen Deaminase gene.
Denaturing gradient gel electrophoresis for rapid detection of latent carriers of a subtype of acute intermittent porphyria with normal erythrocyte porphobilinogen deaminase activity.
Detection of a high mutation frequency in exon 12 of the porphobilinogen deaminase gene in patients with acute intermittent porphyria.
Detection of a R173W mutation in the porphobilinogen deaminase gene in the Nova Scotian "foreign Protestant" population with acute intermittent porphyria: a founder effect.
Detection of eleven mutations causing acute intermittent porphyria using denaturing gradient gel electrophoresis.
Detection of four mutations in six unrelated South African patients with acute intermittent porphyria.
Detection of four novel mutations in the porphobilinogen deaminase gene in French Caucasian patients with acute intermittent porphyria.
Detection of seven point mutations in the porphobilinogen deaminase gene in patients with acute intermittent porphyria, by direct sequencing of in vitro amplified cDNA.
Determination of erythrocyte hydroxymethylbilane synthase activity and its application for study of acute intermittent porphyria.
Determination of porphobilinogen deaminase activity in human erythrocytes: pertinent factors in obtaining optimal conditions for measurements.
Developmental change in activity of red cell porphobilinogen deaminase and its electrophoretic variant in the Japanese population.
Diagnosis and Treatment of Acute Intermittent Porphyria.
Diagnosis of acute intermittent porphyria in northern Sweden: an evaluation of mutation analysis and biochemical methods.
Diagnostic strategies for autosomal dominant acute porphyrias: retrospective analysis of 467 unrelated patients referred for mutational analysis of the HMBS, CPOX, or PPOX gene.
Diagnostic strategy, genetic diagnosis and identification of new mutations in intermittent porphyria by denaturing gradient gel electrophoresis.
Differential diagnosis of acute abdominal pain - acute intermittent porphyria.
Disease pharmacokinetic-pharmacodynamic modelling in acute intermittent porphyria to support the development of mRNA-based therapies.
DNA polymorphism of human porphobilinogen deaminase gene in acute intermittent porphyria.
DNA polymorphisms within the porphobilinogen deaminase gene in two Swedish families with acute intermittent porphyria.
Dysregulation of homocysteine homeostasis in acute intermittent porphyria patients receiving heme arginate or givosiran.
Effect of 5-aminolevulinic acid on the expression of carcinogenesis-related proteins in cultured primary hepatocytes.
Effect of lead on hepatic delta-aminolaevulinic acid synthetase activity in the rat: a model for drug sensitivity in intermittent acute porphyria.
Effects of volatile anaesthetics on heme metabolism in a murine genetic model of Acute Intermittent Porphyria. A comparative study with other porphyrinogenic drugs.
Emerging therapies for acute intermittent porphyria.
Erythrocyte hydroxymethylbilane synthase activity in a Chinese family with acute intermittent porphyria.
Erythrocyte porphobilinogen deaminase activity and primary liver cancer.
Erythrocyte uroporphyrinogen I synthase activity as an indicator of acute porphyria.
Erythrocyte uroporphyrinogen I synthase activity in diagnosis of acute intermittent porphyria.
Evidence for an ancestral founder of the common R116W mutation in the hydroxymethylbilane synthase gene in acute intermittent porphyria in The Netherlands.
Evidence for involvement of a second genetic locus on chromosome 11q in porphyrin metabolism.
Exon 1 donor splice site mutations in the porphobilinogen deaminase gene in the non-erythroid variant form of acute intermittent porphyria.
Expanding the clinical and radiological phenotypes of leukoencephalopathy due to biallelic HMBS mutations.
Experience with the red cell uroporphyrinogen synthase (URO-S) assay in kindreds with acute intermittent porphyria (AIP).
False-positive accumulation of metaiodobenzylguanidine in a case with acute intermittent porphyria.
Family evaluations in acute intermittent porphyria using red cell uroporphyrinogen I synthetase.
Family studies on the activity of uroporphyrinogen I synthase in diagnosis of acute intermittent porphyria.
Feline acute intermittent porphyria: a phenocopy masquerading as an erythropoietic porphyria due to dominant and recessive hydroxymethylbilane synthase mutations.
Femoral and sciatic nerve block for knee arthroscopy in a patient with acute intermittent porphyria.
Four mutations in the porphobilinogen deaminase gene in patients with acute intermittent porphyria.
Frameshift mutations in exons 9 and 10 of the porphobilinogen deaminase gene produce a crossreacting immunological material (CRIM)-negative form of acute intermittent porphyria.
Frequency of low erythrocyte porphobilinogen deaminase activity in Finland.
From a dominant to an oligogenic model of inheritance with environmental modifiers in acute intermittent porphyria.
Gas chromatography-mass spectrometry profiling of steroids in urine of patients with acute intermittent porphyria.
Gene symbol: HMBS. Disease: Acute intermittent porphyria.
Genetic heterogeneity in acute intermittent porphyria: characterisation and frequency of porphobilinogen deaminase mutations in Finland.
Genetic heterogeneity of the porphobilinogen deaminase gene in Swedish families with acute intermittent porphyria.
Genetic investigation of the porphobilinogen deaminase gene in Swedish acute intermittent porphyria families.
Glucose metabolism during fasting is altered in experimental porphobilinogen deaminase deficiency.
Haem precursors and porphobilinogen deaminase in erythrocytes and lymphocytes of patients with acute intermittent porphyria.
Haplotype analysis of Norwegian and Swedish patients with acute intermittent porphyria (AIP): Extreme haplotype heterogeneity for the mutation R116W.
Haplotyping of the human porphobilinogen deaminase gene in acute intermittent porphyria by polymerase chain reaction.
Helper-dependent adenoviral liver gene therapy protects against induced attacks and corrects protein folding stress in acute intermittent porphyria mice.
Helper-dependent adenovirus achieve more efficient and persistent liver transgene expression in non-human primates under immunosuppression.
Heteroduplex analysis detects frameshift and point mutations in patients with acute intermittent porphyria.
Heterogeneity of acute intermittent porphyria: a subtype with normal erythrocyte porphobilinogen deaminase activity in Germany.
High frequency of mutations in exon 10 of the porphobilinogen deaminase gene in patients with a CRIM-positive subtype of acute intermittent porphyria.
High penetrance of acute intermittent porphyria in a Spanish founder mutation population and CYP2D6 genotype as a susceptibility factor.
High prevalence of a point mutation in the porphobilinogen deaminase gene in Dutch patients with acute intermittent porphyria.
High prevalence of and potential mechanisms for chronic kidney disease in patients with acute intermittent porphyria.
Highlights in haem biosynthesis.
HMBS mutations in Chinese patients with acute intermittent porphyria.
Homozygous acute intermittent porphyria: compound heterozygosity for adjacent base transitions in the same codon of the porphobilinogen deaminase gene.
Homozygous hydroxymethylbilane synthase knock-in mice provide pathogenic insights into the severe neurological impairments present in human homozygous dominant acute intermittent porphyria.
Host Porphobilinogen Deaminase Deficiency Confers Malaria Resistance in Plasmodium chabaudi but Not in Plasmodium berghei or Plasmodium falciparum During Intraerythrocytic Growth.
Human hydroxymethylbilane synthase: Molecular dynamics of the pyrrole chain elongation identifies step-specific residues that cause AIP.
Human porphobilinogen deaminase mutations in the investigation of the mechanism of dipyrromethane cofactor assembly and tetrapyrrole formation.
Hydroxymethylbilane Synthase Gene Mutations and Polymorphisms in Brazilian Families with Acute Intermittent Porphyria.
Hydroxymethylbilane synthase: complete genomic sequence and amplifiable polymorphisms in the human gene.
Identification and characterization of 40 novel hydroxymethylbilane synthase mutations that cause acute intermittent porphyria.
Identification and characterization of HMBS gene mutations in Spanish patients with acute intermittent porphyria.
Identification and characterization of hydroxymethylbilane synthase mutations causing acute intermittent porphyria: evidence for an ancestral founder of the common G111R mutation.
Identification and characterization of two novel mutations that produce acute intermittent porphyria: A 3-base deletion (841-843delGGA) and a missense mutation (T35M).
Identification and expression of mutations in the hydroxymethylbilane synthase gene causing acute intermittent porphyria (AIP).
Identification and molecular analysis of 17 novel variants of hydroxymethylbilane synthase in Chinese patients with acute intermittent porphyria.
Identification of a prevalent nonsense mutation (W283X) and two novel mutations in the porphobilinogen deaminase gene of Swiss patients with acute intermittent porphyria.
Identification of acute intermittent porphyria carriers by molecular biologic methods.
Identification of five novel mutations in the porphobilinogen deaminase gene.
Identification of the most common mutation within the porphobilinogen deaminase gene in Swedish patients with acute intermittent porphyria.
Identification of two novel mutations in the hydroxymethylbilane synthase gene in three patients from two unrelated families with acute intermittent porphyria.
Immunological determination of porphobilinogen deaminase as a diagnostic measure in acute intermittent porphyria.
Increased activity of porphobilinogen deaminase in erythrocytes during attacks of acute intermittent porphyria.
Influence of age and gender on the clinical expression of acute intermittent porphyria based on molecular study of porphobilinogen deaminase gene among Swiss patients.
Insertion of Alu element responsible for acute intermittent porphyria.
International Porphyria Molecular Diagnostic Collaborative: an evidence-based database of verified pathogenic and benign variants for the porphyrias.
Lack of effect of pregnancy or hematin therapy on erythrocyte porphobilinogen deaminase activity in acute intermittent porphyria.
Linkage disequilibrium between DNA polymorphisms within the porphobilinogen deaminase gene.
Liver Fibrosis Associated with Iron Accumulation Due to Long-Term Heme-Arginate Treatment in Acute Intermittent Porphyria: A Case Series.
Liver Transplantation for Acute Intermittent Porphyria: Biochemical and Pathologic Studies of the Explanted Liver.
Low-cost uroporphyrinogen I synthase screening for acute intermittent porphyria.
Many pitfalls in diagnosis of acute intermittent porphyria: a case report.
Marked geographic aggregation of acute intermittent porphyria families carrying mutation Q180X in Venezuelan populations, with description of further mutations.
May 2006 update in porphobilinogen deaminase gene polymorphisms and mutations causing acute intermittent porphyria: comparison with the situation in Slavic population.
Mitochondrial energetic defects in muscle and brain of a Hmbs-/- mouse model of acute intermittent porphyria.
Modified erythrocyte uroporphyrinogen I synthase assay, and its clinical interpretation.
Molecular Analysis of 55 Spanish Patients with Acute Intermittent Porphyria.
Molecular analysis of acute intermittent porphyria in a Finnish family with normal erythrocyte porphobilinogen deaminase.
Molecular analysis of porphobilinogen (PBG) deaminase gene mutations in acute intermittent porphyria: first study in patients of Slavic origin.
Molecular analysis of the hydroxymethylbilane synthase (HMBS) gene in Italian patients with acute intermittent porphyria: report of four novel mutations.
Molecular basis of acute intermittent porphyria.
Molecular basis of acute intermittent porphyria: mutations and polymorphisms in the human hydroxymethylbilane synthase gene.
Molecular characterisation of acute intermittent porphyria in a cohort of South African patients and kinetic analysis of two expressed mutants.
Molecular characterization, by digital PCR analysis of four HMBS gene mutations affecting the ubiquitous isoform of Porphobilinogen Deaminase (PBGD) in patients with Acute Intermittent Porphyria (AIP).
Molecular diagnosis of acute intermittent porphyria by analysis of DNA extracted from hair roots.
Molecular epidemiology and diagnosis of PBG deaminase gene defects in acute intermittent porphyria.
Molecular forms of porphobilinogen deaminase in acute intermittent porphyria. A study by Western immunoblotting.
Molecular genetic study of acute intermittent porphyria in Russia: HMBS gene mutation spectrum and problem of penetrance.
Molecular study of the hydroxymethylbilane synthase gene (HMBS) among Polish patients with acute intermittent porphyria.
Mutation in the exon 10 (R173W) of the hydroxymethylbilane synthase gene in two unrelated Japanese families with acute intermittent porphyria.
Mutations in acute intermittent porphyria detected by ELISA measurement of porphobilinogen deaminase.
Nerve function and dysfunction in acute intermittent porphyria.
Network analysis of hydroxymethylbilane synthase dynamics.
Neurological manifestations of acute intermittent porphyria.
New mutations of the hydroxymethylbilane synthase gene in German patients with acute intermittent porphyria.
Nine mutations including three novel mutations among Russian patients with acute intermittent porphyria.
Nine novel mutations in the hydroxymethylbilane synthase gene of Polish patients with acute intermittent porphyria.
Non-erythroid form of acute intermittent porphyria caused by promoter and frameshift mutations distant from the coding sequence of exon 1 of the HMBS gene.
Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria.
Non-viral mediated gene transfer of porphobilinogen deaminase into mammalian cells.
Normal erythrocyte uroporphyrinogen I synthase in a kindred with acute intermittent porphyria.
Novel A219P mutation of hydroxymethylbilane synthase identified in a Chinese woman with acute intermittent porphyria and syndrome of inappropriate antidiuretic hormone.
Novel HMBS founder mutation and significant intronic polymorphism in Spanish patients with acute intermittent porphyria.
Novel human pathological mutations. Gene symbol: HMBS. Disease: Acute intermittent porphyria.
Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria.
PORPHOBILINOGEN DEAMINASE deficiency alters vegetative and reproductive development and causes lesions in Arabidopsis.
Porphobilinogen deaminase deficiency in mice causes a neuropathy resembling that of human hepatic porphyria.
Porphobilinogen deaminase gene in African and Afro-Caribbean ethnic groups: mutations causing acute intermittent porphyria and specific intragenic polymorphisms.
Porphobilinogen deaminase gene mutations in Polish patients with non-erythroid acute intermittent porphyria.
Porphobilinogen deaminase gene structure and molecular defects.
Porphobilinogen deaminase in acute intermittent porphyria: activity and concentration in erythrocytes and lymphocytes.
Porphobilinogen deaminase over-expression in hepatocytes, but not in erythrocytes, prevents accumulation of toxic porphyrin precursors in a mouse model of acute intermittent porphyria.
Porphyria presenting with bilateral radial motor neuropathy: evidence of a novel gene mutation.
Prevalence of acute intermittent porphyria in a Mexican psychiatric population.
Proteasomal degradation regulates expression of porphobilinogen deaminase (PBGD) mutants of acute intermittent porphyria.
Pseudoexon activation in the HMBS gene as a cause of the nonerythroid form of acute intermittent porphyria.
Purple pigments: The pathophysiology of acute porphyric neuropathy.
R325X mutation in exon 15 of the hydroxymethylbilane synthase gene identified in two Danish families with acute intermittent porphyria.
Rat kidney porphobilinogen deaminase kinetics. Detection of enzyme-substrate complexes.
Recent advances in the epidemiology and genetics of acute intermittent porphyria.
Recurrence risk estimation of acute intermittent porphyria based on analysis of porphobilinogen deaminase activity: a Bayesian approach.
Recurrent attacks of acute hepatic porphyria: major role of the chronic inflammatory response in the liver.
Recurrent Seizures in an Adolescent Female-A Daunting Puzzle.
Red blood cell porphobilinogen deaminase in the evaluation of acute intermittent porphyria.
Red cell uroporphyrinogen I synthetase in acute intermittent porphyria.
Reference values of 5-aminolevulinate dehydrase and porphobilinogen deaminase in the Spanish population from Madrid.
Renal transplantation in a case of acute intermittent porphyria.
Residual activity of human porphobilinogen deaminase with R167Q or R167W mutations: an explanation for survival of homozygous and compound heterozygous acute intermittent porphyrics.
Reversible MRI findings in a case of acute intermittent porphyria with a novel mutation in the porphobilinogen deaminase gene.
Reversible splenial lesion syndrome (RESLES) due to acute intermittent porphyria with a novel mutation in the hydroxymethylbilane synthase gene.
RFLP analysis of three different types of acute intermittent porphyria.
Role of two nutritional hepatic markers (insulin-like growth factor 1 and transthyretin) in the clinical assessment and follow-up of acute intermittent porphyria patients.
Safety and liver transduction efficacy of rAAV5-cohPBGD in non-human primates: A potential therapy for Acute Intermitent Porphyria.
Safety, pharmacokinetics and pharmocodynamics of recombinant human porphobilinogen deaminase in healthy subjects and asymptomatic carriers of the acute intermittent porphyria gene who have increased porphyrin precursor excretion.
Seven novel genetic mutations within the 5'UTR and the housekeeping promoter of HMBS gene responsible for the non-erythroid form of acute intermittent porphyria.
Seven Novel Mutations in Bulgarian Patients with Acute Hepatic Porphyrias (AHP).
Severe hydroxymethylbilane synthase deficiency causes depression-like behavior and mitochondrial dysfunction in a mouse model of homozygous dominant acute intermittent porphyria.
Sevoflurane: its action on heme metabolism and Phase I drug metabolizing system.
Sex differences in vascular reactivity in mesenteric arteries from a mouse model of acute intermittent porphyria.
Steady-state transcript levels of the porphobilinogen deaminase gene in patients with acute intermittent porphyria.
Structure of human porphobilinogen deaminase at 2.8 A: the molecular basis of acute intermittent porphyria.
Studies in porphyria. IV. Expression of the gene defect of acute intermittent porphyria in cultured human skin fibroblasts and amniotic cells: prenatal diagnosis of the porphyric trait.
Sustained Enzymatic Correction by rAAV-Mediated Liver Gene Therapy Protects Against Induced Motor Neuropathy in Acute Porphyria Mice.
Systematically Analyzing the Pathogenic Variations for Acute Intermittent Porphyria.
Systemic Administered mRNA as Therapy for Metabolic Diseases.
Systemic messenger RNA as an etiological treatment for acute intermittent porphyria.
The diagnosis of acute intermittent porphyria. Usefulness and limitations of the erythrocyte uroporphyrinogen I synthase assay.
The effect of therapeutic drugs and other pharmacologic agents on activity of porphobilinogen deaminase, the enzyme that is deficient in intermittent acute porphyria.
The three-dimensional structures of mutants of porphobilinogen deaminase: toward an understanding of the structural basis of acute intermittent porphyria.
The tolerability of newer immunosuppressive medications in a patient with acute intermittent porphyria.
The use of rocuronium and sevoflurane in acute intermittent porphyria--a case report.
The W198X and R173W mutations in the porphobilinogen deaminase gene in acute intermittent porphyria have higher clinical penetrance than R167W. A population-based study.
Therapeutic strategies for acute intermittent porphyria.
Three splicing defects, an insertion, and two missense mutations responsible for acute intermittent porphyria.
Tissue-specific expression of porphobilinogen deaminase. Two isoenzymes from a single gene.
Tissue-specific splicing mutation in acute intermittent porphyria.
Two deletion mutations in the hydroxymethylbilane synthase gene in two unrelated Japanese patients with acute intermittent porphyria.
Two different point G to A mutations in exon 10 of the porphobilinogen deaminase gene are responsible for acute intermittent porphyria.
Two new mutations in the porphobilinogen deaminase gene and a screening method using PCR amplification of specific alleles.
Two novel mutations of the porphobilinogen deaminase gene in acute intermittent porphyria.
Updates on the diagnosis and management of the most common hereditary porphyrias: AIP and EPP.
Uroporphyrinogen synthetase in erythrocytes. Its diagnostic value in latent acute intermittent porphyria with special regard to the gene penetrance.
Validation and evaluation of two porphobilinogen deaminase activity assays for diagnosis of acute intermittent porphyria.
Variable phenotypic expression of genotypic abnormalities in the porphyrias.
Variegate porphyria with coexistent decrease in porphobilinogen deaminase activity.
Vitamin D-binding protein as a biomarker of active disease in acute intermittent porphyria.
Whole Exome Sequencing Identified a Novel Heterozygous Mutation in HMBS Gene in a Chinese Patient With Acute Intermittent Porphyria With Rare Type of Mild Anemia.
[A 25-year-old patient with colonic pseudo-obstruction, hyponatremia, hypertension, and diffuse pain]
[Acute intermittent porphyria and chronic transaminase elevation]
[Acute intermittent porphyria in the puerperium].
[Acute intermittent porphyria. Detection of asymptomatic carriers of the genetic defect]
[Acute intermittent porphyria: Long-term follow up of 35 patients].
[Acute intermittent porphyria]
[Determination of uroporphyrinogen I synthase in whole blood--a method for the diagnosis and early recognition of acute intermittent porphyria]
[Diagnosis of acute intermittent porphyria on the basis of uroporphyrinogen I synthase activity in the erythrocytes; comparison of 2 methods]
[Enzyme deficiency of erythrocytes in human porphyria]
[Evaluation of the diagnostic usefulness of determining porphobilinogen deaminase activity in the erythrocytes in patients with acute intermittent porphyria and in carriers of the gene of this type of porphyria]
[Letter: Determination of uroporphyrinogen I synthetase in intermittent acute porphyria. 7 cases]
[Molecular genetic study of acute intermittent porphyria in Russia: mutation analysis and functional polymorphism search in porphobilinogen deaminase gene]
[Normal activity of uroporphyrinogen I synthase during an attack of acute intermittent porphyria]
[Plasma and salivary markers of oxidative and carbonyl stress in patients with acute intermittent porphyria].
[The initial results of detecting mutations in the gene of the porphobilinogen deaminase enzyme in patients with acute intermittent porphyria in Russia]
[Three new mutations in the porphobilinogen deaminase gene, detected in acute intermittent porphyria patients from Russia]
[Three single nucleotide polymorphisms of porphobilinogen deaminase gene related to a Chinese patient with acute intermittent porphyria]
[Uroporphyrinogen synthase in erythrocytes in acute intermittent porphyria: new pathobiochemical aspects (author's transl)]
Porphyria, Erythropoietic
Coupled-enzyme and direct assays for uroporphyrinogen III synthase activity in human erythrocytes and cultured lymphoblasts. Enzymatic diagnosis of heterozygotes and homozygotes with congenital erythropoietic porphyria.
Feline acute intermittent porphyria: a phenocopy masquerading as an erythropoietic porphyria due to dominant and recessive hydroxymethylbilane synthase mutations.
The activities of uroporphyrinogen synthetase and cosynthetase in congenital erythropoietic porphyria (CEP).
Uroporphyrinogen-III synthase: molecular cloning, nucleotide sequence, expression of a mouse full-length cDNA, and its localization on mouse chromosome 7.
[Pathobiochemical observations on porphyrias--the correlation between uroporphyrinogen I synthetase and III cosynthetase activity in congenital erythropoietic porphyria (author's transl)]
Porphyria, Variegate
A next-generation-sequencing panel for mutational analysis of dominant acute hepatic porphyrias.
Allosteric inhibition of human lymphoblast and purified porphobilinogen deaminase by protoporphyrinogen and coproporphyrinogen. A possible mechanism for the acute attack of variegate porphyria.
Biallelic inactivation of protoporphyrinogen oxidase and hydroxymethylbilane synthase is associated with liver cancer in acute porphyrias.
Chester porphyria: biochemical studies of a new form of acute porphyria.
International Porphyria Molecular Diagnostic Collaborative: an evidence-based database of verified pathogenic and benign variants for the porphyrias.
Kidney damage in acute intermittent porphyria.
Protoporphyrinogen oxidase and porphobilinogen deaminase in variegate porphyria.
Red cell uroporphyrinogen I synthetase in acute intermittent porphyria.
Seven Novel Mutations in Bulgarian Patients with Acute Hepatic Porphyrias (AHP).
Variegate porphyria with coexistent decrease in porphobilinogen deaminase activity.
Porphyrias
"Glucose effect" and rate limiting function of uroporphyrinogen synthase on porphyrin metabolism in hepatocyte culture: relationship with human acute hepatic porphyrias.
A large deletion on chromosome 11 in acute intermittent porphyria.
A microassay for uroporphyrinogen I synthase, one of three abnormal enzyme activities in acute intermittent porphyria, and its application to the study of the genetics of this disease.
A modified spectrophotometric assay for porphobilinogen deaminase: its application in the detection of both carriers and patients with acute intermittent porphyria.
A new mutation within the porphobilinogen deaminase gene leading to a truncated protein as a cause of acute intermittent porphyria in an extended Indian family.
A next-generation-sequencing panel for mutational analysis of dominant acute hepatic porphyrias.
A novel 12-base pair deletion mutation in exon 15 of the porphobilinogen deaminase gene in a Taiwanese patient with acute intermittent porphyria.
A novel 19-bp deletion of exon 15 in the HMBS gene causing acute intermittent porphyria associating with rhabdomyolysis during an acute attack.
A novel 55-basepair deletion of hydroxymethylbilane synthase gene found in a Chinese patient with acute intermittent porphyria and her family: A case report.
A novel G168X mutation and a recurrent 730-731delCT mutation of the porphobilinogen deaminase gene in Japanese patients with acute intermittent porphyria.
A novel heterozygous mutation in the HMBS gene in a patient with acute intermittent porphyria and posterior reversible encephalopathy syndrome.
A novel mutation in a family with non-erythroid variant form of acute intermittent porphyria.
A novel mutation in the porphobilinogen deaminase gene in an extended Chinese family with acute intermittent porphyria.
A Pharmacological Chaperone Therapy for Acute Intermittent Porphyria.
A point mutation G----A in exon 12 of the porphobilinogen deaminase gene results in exon skipping and is responsible for acute intermittent porphyria.
A point mutation, C to T, in exon 8 of the porphobilinogen deaminase gene in a Japanese family with acute intermittent porphyria.
A rare case of acute intermittent porphyria with ichthyosis vulgaris in a young boy.
A splicing mutation in the hydroxymethylbilane synthase gene in a Japanese family with acute intermittent porphyria.
AAV8-mediated Gene Therapy Prevents Induced Biochemical Attacks of Acute Intermittent Porphyria and Improves Neuromotor Function.
Abnormal thyroid function and hypercholesterolemia in a case of acute intermittent porphyria.
Acute hepatic porphyrias: Identification of 46 hydroxymethylbilane synthase, 11 coproporphyrinogen oxidase, and 20 protoporphyrinogen oxidase novel mutations.
Acute intermittent porphyria and mental illness--a family study.
Acute intermittent porphyria and uroporphyrinogen I synthase. Biochemical study of a family.
Acute intermittent porphyria as a cause of respiratory failure: case report.
Acute intermittent porphyria caused by a C----T mutation that produces a stop codon in the porphobilinogen deaminase gene.
Acute intermittent porphyria caused by a G to C mutation in exon 12 of the porphobilinogen deaminase gene that results in exon skipping.
Acute intermittent porphyria caused by a single base insertion of C in exon 15 of the porphobilinogen deaminase gene that results in a frame shift and premature stopping of translation.
Acute intermittent porphyria caused by an arginine to histidine substitution (R26H) in the cofactor-binding cleft of porphobilinogen deaminase.
Acute intermittent porphyria caused by defective splicing of porphobilinogen deaminase RNA: a synonymous codon mutation at -22 bp from the 5' splice site causes skipping of exon 3.
Acute intermittent porphyria caused by novel mutation in HMBS gene, misdiagnosed as cholecystitis.
Acute Intermittent Porphyria Causes Hepatic Mitochondrial Energetic Failure In A Mouse Model.
Acute Intermittent Porphyria in a Man with Dual Enzyme Deficiencies.
Acute intermittent porphyria in Argentina: an update.
Acute intermittent porphyria in Finland: 19 mutations in the porphobilinogen deaminase gene.
Acute intermittent porphyria in Sweden. Molecular, functional and clinical consequences of some new mutations found in the porphobilinogen deaminase gene.
Acute intermittent porphyria in The Netherlands. Heterogeneity of the enzyme porphobilinogen deaminase.
Acute intermittent porphyria in two patients on anticonvulsant therapy and with normal erythrocyte porphobilinogen deaminase activity.
Acute Intermittent Porphyria Presenting with Posterior Reversible Encephalopathy Syndrome: A Rare Cause of Abdominal Pain and Seizures.
Acute intermittent porphyria with transient cortical blindness.
Acute intermittent porphyria--impact of mutations found in the hydroxymethylbilane synthase gene on biochemical and enzymatic protein properties.
Acute intermittent porphyria-related leukoencephalopathy.
Acute intermittent porphyria: A case report
Acute intermittent porphyria: a single-base deletion and a nonsense mutation in the human hydroxymethylbilane synthase gene, predicting truncations of the enzyme polypeptide.
Acute intermittent porphyria: a test of clinical acumen.
Acute intermittent porphyria: alternative splicing of hydroxymethylbilane synthase mRNA excludes exons 3 and 12.
Acute Intermittent Porphyria: An Overview of Therapy Developments and Future Perspectives Focusing on Stabilisation of HMBS and Proteostasis Regulators.
Acute intermittent porphyria: characterization of a novel mutation in the structural gene for porphobilinogen deaminase. Demonstration of noncatalytic enzyme intermediates stabilized by bound substrate.
Acute intermittent porphyria: characterization of two novel mutations in the porphobilinogen deaminase gene, one amino acid deletion (453-455delAGC) and one splicing aceptor site mutation (IVS8-1G>T).
Acute intermittent porphyria: clinicopathologic correlation. Report of a case and review of the literature.
Acute intermittent porphyria: diagnostic conundrums.
Acute intermittent porphyria: expression of mutant and wild-type porphobilinogen deaminase in COS-1 cells.
Acute intermittent porphyria: focus on possible mechanisms of acute and chronic manifestations.
Acute intermittent porphyria: heterogeneity of mutations in the hydroxymethylbilane synthase gene in Italy.
Acute intermittent porphyria: identification and expression of exonic mutations in the hydroxymethylbilane synthase gene. An initiation codon missense mutation in the housekeeping transcript causes "variant acute intermittent porphyria" with normal expression of the erythroid-specific enzyme.
Acute intermittent porphyria: novel missense mutations in the human hydroxymethylbilane synthase gene.
Acute intermittent porphyria: pathophysiology and treatment.
Acute Intermittent Porphyria: Predicted Pathogenicity of HMBS Variants Indicates Extremely Low Penetrance of the Autosomal Dominant Disease.
Acute intermittent porphyria: prevalence of mutations in the porphobilinogen deaminase gene in blood donors in France.
Acute intermittent porphyria: studies of the severe homozygous dominant disease provides insights into the neurologic attacks in acute porphyrias.
Acute intermittent porphyria: the in vitro expression of mutant hydroxymethylbilane synthase.
Acute intermittent porphyria: vector optimization for gene therapy.
Acute porphyrias in the Argentinean population: a review.
Adenoviral-mediated expression of porphobilinogen deaminase in liver restores the metabolic defect in a mouse model of acute intermittent porphyria.
Adrenal hormonal imbalance in acute intermittent porphyria patients: results of a case control study.
Allosteric inhibition of human lymphoblast and purified porphobilinogen deaminase by protoporphyrinogen and coproporphyrinogen. A possible mechanism for the acute attack of variegate porphyria.
An Inducible Promoter Responsive to Different Porphyrinogenic Stimuli Improves Gene Therapy Vectors for Acute Intermittent Porphyria.
An unusual cause of syndrome of inappropriate antidiuretic hormone secretion.
An update of clinical management of acute intermittent porphyria.
Ancestral founder of mutation W283X in the porphobilinogen deaminase gene among acute intermittent porphyria patients.
Anesthesia in a child with homozygous porphobilinogen deaminase deficiency: a severe form of acute intermittent porphyria.
Assay for erythrocyte uroporphyrinogen I synthase activity, with porphobilinogen as substrate.
Biallelic inactivation of protoporphyrinogen oxidase and hydroxymethylbilane synthase is associated with liver cancer in acute porphyrias.
Biochemical and hematological analysis in acute intermittent porphyria (AIP): a case report.
Biochemical characterization of porphobilinogen deaminase-deficient mice during phenobarbital induction of heme synthesis and the effect of enzyme replacement.
Biochemical differentiation of the porphyrias.
Bioengineered PBGD variant improves the therapeutic index of gene therapy vectors for acute intermittent porphyria.
Carbamazepine-induced non-hereditary acute porphyria.
Characterization of the hepatic transcriptome following phenobarbital induction in mice with AIP.
Characterization of the porphobilinogen deaminase deficiency in acute intermittent porphyria. Immunologic evidence for heterogeneity of the genetic defect.
Characterization of two isoalleles and three mutations in both isoforms of purified recombinant human porphobilinogen deaminase.
Characterization of two missense variants in the hydroxymethylbilane synthase gene in the Israeli population, which differ in their associations with acute intermittent porphyria.
Chester porphyria: biochemical studies of a new form of acute porphyria.
Circulating fluorocytes at the first attack of acute intermittent porphyria: A missing link in the pathogenesis.
Clinical and biochemical characteristics and genotype-phenotype correlation in 143 Finnish and Russian patients with acute intermittent porphyria.
Comparison of complementary and genomic DNA sequencing for the detection of mutations in the HMBS gene in British patients with acute intermittent porphyria: identification of 25 novel mutations.
Comprehensive analysis of the tryptophan metabolome in urine of patients with acute intermittent porphyria.
Conformational stability and activity analysis of two hydroxymethylbilane synthase mutants, K132N and V215E, with different phenotypic association with acute intermittent porphyria.
Correction of the biochemical defect in porphobilinogen deaminase deficient cells by non-viral gene delivery.
Correlation between biochemical findings, structural and enzymatic abnormalities in mutated HMBS identified in six Israeli families with acute intermittent porphyria.
CRIM-positive mutations of acute intermittent porphyria in Finland.
Danazol administration to females with menses-associated exacerbations of acute intermittent porphyria.
De Novo mutation found in the porphobilinogen deaminase gene in Slovak acute intermittent porphyria patient: molecular biochemical study.
Decreased nocturnal plasma melatonin levels in patients with recurrent acute intermittent porphyria attacks.
Demystification of Chester porphyria: a nonsense mutation in the Porphobilinogen Deaminase gene.
Denaturing gradient gel electrophoresis for rapid detection of latent carriers of a subtype of acute intermittent porphyria with normal erythrocyte porphobilinogen deaminase activity.
Detection of a high mutation frequency in exon 12 of the porphobilinogen deaminase gene in patients with acute intermittent porphyria.
Detection of a R173W mutation in the porphobilinogen deaminase gene in the Nova Scotian "foreign Protestant" population with acute intermittent porphyria: a founder effect.
Detection of eleven mutations causing acute intermittent porphyria using denaturing gradient gel electrophoresis.
Detection of four mutations in six unrelated South African patients with acute intermittent porphyria.
Detection of four novel mutations in the porphobilinogen deaminase gene in French Caucasian patients with acute intermittent porphyria.
Detection of seven point mutations in the porphobilinogen deaminase gene in patients with acute intermittent porphyria, by direct sequencing of in vitro amplified cDNA.
Determination of erythrocyte hydroxymethylbilane synthase activity and its application for study of acute intermittent porphyria.
Determination of porphobilinogen deaminase activity in human erythrocytes: pertinent factors in obtaining optimal conditions for measurements.
Developmental change in activity of red cell porphobilinogen deaminase and its electrophoretic variant in the Japanese population.
Diagnosis and Treatment of Acute Intermittent Porphyria.
Diagnosis of acute intermittent porphyria in northern Sweden: an evaluation of mutation analysis and biochemical methods.
Diagnostic strategy, genetic diagnosis and identification of new mutations in intermittent porphyria by denaturing gradient gel electrophoresis.
Differential diagnosis of acute abdominal pain - acute intermittent porphyria.
Direct assay of enzymes in heme biosynthesis for the detection of porphyrias by tandem mass spectrometry. Porphobilinogen deaminase.
Disease pharmacokinetic-pharmacodynamic modelling in acute intermittent porphyria to support the development of mRNA-based therapies.
DNA polymorphism of human porphobilinogen deaminase gene in acute intermittent porphyria.
DNA polymorphisms within the porphobilinogen deaminase gene in two Swedish families with acute intermittent porphyria.
Dual porphyria in double heterozygotes with porphobilinogen deaminase and uroporphyrinogen decarboxylase deficiencies.
Dual porphyria with mutations in both the UROD and HMBS genes.
Dysregulation of homocysteine homeostasis in acute intermittent porphyria patients receiving heme arginate or givosiran.
Effect of 5-aminolevulinic acid on the expression of carcinogenesis-related proteins in cultured primary hepatocytes.
Effects of volatile anaesthetics on heme metabolism in a murine genetic model of Acute Intermittent Porphyria. A comparative study with other porphyrinogenic drugs.
Emerging therapies for acute intermittent porphyria.
Erythrocyte hydroxymethylbilane synthase activity in a Chinese family with acute intermittent porphyria.
Erythrocyte porphobilinogen deaminase activity and primary liver cancer.
Erythrocyte porphobilinogen deaminase activity in porphyria cutanea tarda.
Erythrocyte uroporphyrinogen I synthase activity in diagnosis of acute intermittent porphyria.
Evidence for an ancestral founder of the common R116W mutation in the hydroxymethylbilane synthase gene in acute intermittent porphyria in The Netherlands.
Evidence for involvement of a second genetic locus on chromosome 11q in porphyrin metabolism.
Exon 1 donor splice site mutations in the porphobilinogen deaminase gene in the non-erythroid variant form of acute intermittent porphyria.
Expanding the clinical and radiological phenotypes of leukoencephalopathy due to biallelic HMBS mutations.
Experience with the red cell uroporphyrinogen synthase (URO-S) assay in kindreds with acute intermittent porphyria (AIP).
False-positive accumulation of metaiodobenzylguanidine in a case with acute intermittent porphyria.
Family evaluations in acute intermittent porphyria using red cell uroporphyrinogen I synthetase.
Family studies on the activity of uroporphyrinogen I synthase in diagnosis of acute intermittent porphyria.
Feline acute intermittent porphyria: a phenocopy masquerading as an erythropoietic porphyria due to dominant and recessive hydroxymethylbilane synthase mutations.
Femoral and sciatic nerve block for knee arthroscopy in a patient with acute intermittent porphyria.
Four mutations in the porphobilinogen deaminase gene in patients with acute intermittent porphyria.
Frameshift mutations in exons 9 and 10 of the porphobilinogen deaminase gene produce a crossreacting immunological material (CRIM)-negative form of acute intermittent porphyria.
Frequency of low erythrocyte porphobilinogen deaminase activity in Finland.
From a dominant to an oligogenic model of inheritance with environmental modifiers in acute intermittent porphyria.
Gas chromatography-mass spectrometry profiling of steroids in urine of patients with acute intermittent porphyria.
Gene symbol: HMBS. Disease: Acute intermittent porphyria.
Gene symbol: HMBS. Disease: porphyria, acute intermittent.
Gene symbol: HMBS. Disease: Porphyria, acute intermittent.
Gene symbol: HMBS. Disease: porphyria, acute intermittent.
Gene symbol: HMBS. Disease: Porphyria, acute intermittent.
Genetic heterogeneity in acute intermittent porphyria: characterisation and frequency of porphobilinogen deaminase mutations in Finland.
Genetic heterogeneity of the porphobilinogen deaminase gene in Swedish families with acute intermittent porphyria.
Genetic investigation of the porphobilinogen deaminase gene in Swedish acute intermittent porphyria families.
Glucose metabolism during fasting is altered in experimental porphobilinogen deaminase deficiency.
Haem precursors and porphobilinogen deaminase in erythrocytes and lymphocytes of patients with acute intermittent porphyria.
Haplotype analysis of Norwegian and Swedish patients with acute intermittent porphyria (AIP): Extreme haplotype heterogeneity for the mutation R116W.
Haplotyping of the human porphobilinogen deaminase gene in acute intermittent porphyria by polymerase chain reaction.
Helper-dependent adenoviral liver gene therapy protects against induced attacks and corrects protein folding stress in acute intermittent porphyria mice.
Helper-dependent adenovirus achieve more efficient and persistent liver transgene expression in non-human primates under immunosuppression.
Hepatocyte transplantation ameliorates the metabolic abnormality in a mouse model of acute intermittent porphyria.
Heteroduplex analysis detects frameshift and point mutations in patients with acute intermittent porphyria.
Heterogeneity of acute intermittent porphyria: a subtype with normal erythrocyte porphobilinogen deaminase activity in Germany.
High frequency of mutations in exon 10 of the porphobilinogen deaminase gene in patients with a CRIM-positive subtype of acute intermittent porphyria.
High penetrance of acute intermittent porphyria in a Spanish founder mutation population and CYP2D6 genotype as a susceptibility factor.
High prevalence of a point mutation in the porphobilinogen deaminase gene in Dutch patients with acute intermittent porphyria.
High prevalence of and potential mechanisms for chronic kidney disease in patients with acute intermittent porphyria.
Highlights in haem biosynthesis.
HMBS mutations in Chinese patients with acute intermittent porphyria.
Homozygous acute intermittent porphyria: compound heterozygosity for adjacent base transitions in the same codon of the porphobilinogen deaminase gene.
Homozygous hydroxymethylbilane synthase knock-in mice provide pathogenic insights into the severe neurological impairments present in human homozygous dominant acute intermittent porphyria.
Human hydroxymethylbilane synthase: Molecular dynamics of the pyrrole chain elongation identifies step-specific residues that cause AIP.
Human porphobilinogen deaminase mutations in the investigation of the mechanism of dipyrromethane cofactor assembly and tetrapyrrole formation.
Hydroxymethylbilane Synthase Gene Mutations and Polymorphisms in Brazilian Families with Acute Intermittent Porphyria.
Hydroxymethylbilane synthase: complete genomic sequence and amplifiable polymorphisms in the human gene.
Identification and characterization of 40 novel hydroxymethylbilane synthase mutations that cause acute intermittent porphyria.
Identification and characterization of HMBS gene mutations in Spanish patients with acute intermittent porphyria.
Identification and characterization of hydroxymethylbilane synthase mutations causing acute intermittent porphyria: evidence for an ancestral founder of the common G111R mutation.
Identification and characterization of two novel mutations that produce acute intermittent porphyria: A 3-base deletion (841-843delGGA) and a missense mutation (T35M).
Identification and expression of mutations in the hydroxymethylbilane synthase gene causing acute intermittent porphyria (AIP).
Identification and molecular analysis of 17 novel variants of hydroxymethylbilane synthase in Chinese patients with acute intermittent porphyria.
Identification of a prevalent nonsense mutation (W283X) and two novel mutations in the porphobilinogen deaminase gene of Swiss patients with acute intermittent porphyria.
Identification of acute intermittent porphyria carriers by molecular biologic methods.
Identification of five novel mutations in the porphobilinogen deaminase gene.
Identification of the most common mutation within the porphobilinogen deaminase gene in Swedish patients with acute intermittent porphyria.
Identification of two novel mutations in the hydroxymethylbilane synthase gene in three patients from two unrelated families with acute intermittent porphyria.
Immunological determination of porphobilinogen deaminase as a diagnostic measure in acute intermittent porphyria.
Increased activity of porphobilinogen deaminase in erythrocytes during attacks of acute intermittent porphyria.
Influence of age and gender on the clinical expression of acute intermittent porphyria based on molecular study of porphobilinogen deaminase gene among Swiss patients.
Insertion of Alu element responsible for acute intermittent porphyria.
International Porphyria Molecular Diagnostic Collaborative: an evidence-based database of verified pathogenic and benign variants for the porphyrias.
Lack of effect of pregnancy or hematin therapy on erythrocyte porphobilinogen deaminase activity in acute intermittent porphyria.
Linkage disequilibrium between DNA polymorphisms within the porphobilinogen deaminase gene.
Liver Fibrosis Associated with Iron Accumulation Due to Long-Term Heme-Arginate Treatment in Acute Intermittent Porphyria: A Case Series.
Liver Transplantation for Acute Intermittent Porphyria: Biochemical and Pathologic Studies of the Explanted Liver.
Low-cost uroporphyrinogen I synthase screening for acute intermittent porphyria.
Many pitfalls in diagnosis of acute intermittent porphyria: a case report.
Marked geographic aggregation of acute intermittent porphyria families carrying mutation Q180X in Venezuelan populations, with description of further mutations.
May 2006 update in porphobilinogen deaminase gene polymorphisms and mutations causing acute intermittent porphyria: comparison with the situation in Slavic population.
Mitochondrial energetic defects in muscle and brain of a Hmbs-/- mouse model of acute intermittent porphyria.
Modified erythrocyte uroporphyrinogen I synthase assay, and its clinical interpretation.
Molecular Analysis of 55 Spanish Patients with Acute Intermittent Porphyria.
Molecular analysis of acute intermittent porphyria in a Finnish family with normal erythrocyte porphobilinogen deaminase.
Molecular analysis of porphobilinogen (PBG) deaminase gene mutations in acute intermittent porphyria: first study in patients of Slavic origin.
Molecular analysis of the hydroxymethylbilane synthase (HMBS) gene in Italian patients with acute intermittent porphyria: report of four novel mutations.
Molecular basis of acute intermittent porphyria.
Molecular basis of acute intermittent porphyria: mutations and polymorphisms in the human hydroxymethylbilane synthase gene.
Molecular characterisation of acute intermittent porphyria in a cohort of South African patients and kinetic analysis of two expressed mutants.
Molecular characterization of porphyrias in Italy: a diagnostic flow-chart.
Molecular characterization, by digital PCR analysis of four HMBS gene mutations affecting the ubiquitous isoform of Porphobilinogen Deaminase (PBGD) in patients with Acute Intermittent Porphyria (AIP).
Molecular diagnosis of acute intermittent porphyria by analysis of DNA extracted from hair roots.
Molecular epidemiology and diagnosis of PBG deaminase gene defects in acute intermittent porphyria.
Molecular forms of porphobilinogen deaminase in acute intermittent porphyria. A study by Western immunoblotting.
Molecular genetic study of acute intermittent porphyria in Russia: HMBS gene mutation spectrum and problem of penetrance.
Molecular study of the hydroxymethylbilane synthase gene (HMBS) among Polish patients with acute intermittent porphyria.
Mutation in the exon 10 (R173W) of the hydroxymethylbilane synthase gene in two unrelated Japanese families with acute intermittent porphyria.
Mutations in acute intermittent porphyria detected by ELISA measurement of porphobilinogen deaminase.
Nerve function and dysfunction in acute intermittent porphyria.
Network analysis of hydroxymethylbilane synthase dynamics.
Neurological manifestations of acute intermittent porphyria.
New mutations of the hydroxymethylbilane synthase gene in German patients with acute intermittent porphyria.
Nine mutations including three novel mutations among Russian patients with acute intermittent porphyria.
Nine novel mutations in the hydroxymethylbilane synthase gene of Polish patients with acute intermittent porphyria.
Non-erythroid form of acute intermittent porphyria caused by promoter and frameshift mutations distant from the coding sequence of exon 1 of the HMBS gene.
Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria.
Non-viral mediated gene transfer of porphobilinogen deaminase into mammalian cells.
Normal erythrocyte uroporphyrinogen I synthase in a kindred with acute intermittent porphyria.
Novel A219P mutation of hydroxymethylbilane synthase identified in a Chinese woman with acute intermittent porphyria and syndrome of inappropriate antidiuretic hormone.
Novel HMBS founder mutation and significant intronic polymorphism in Spanish patients with acute intermittent porphyria.
Novel human pathological mutations. Gene symbol: HMBS. Disease: Acute intermittent porphyria.
Novel human pathological mutations. Gene symbol: HMBS. Disease: porphyria, acute intermittent.
Novel human pathological mutations. Gene symbol: HMBS. Disease: Porphyria, acute intermittent.
Novel human pathological mutations. Gene symbol: HMBS. Disease: porphyria, acute intermittent.
Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria.
Porphobilinogen deaminase deficiency in mice causes a neuropathy resembling that of human hepatic porphyria.
Porphobilinogen deaminase gene in African and Afro-Caribbean ethnic groups: mutations causing acute intermittent porphyria and specific intragenic polymorphisms.
Porphobilinogen deaminase gene mutations in Polish patients with non-erythroid acute intermittent porphyria.
Porphobilinogen deaminase gene structure and molecular defects.
Porphobilinogen deaminase in acute intermittent porphyria: activity and concentration in erythrocytes and lymphocytes.
Porphobilinogen deaminase over-expression in hepatocytes, but not in erythrocytes, prevents accumulation of toxic porphyrin precursors in a mouse model of acute intermittent porphyria.
Porphyria presenting with bilateral radial motor neuropathy: evidence of a novel gene mutation.
Prevalence of acute intermittent porphyria in a Mexican psychiatric population.
Proteasomal degradation regulates expression of porphobilinogen deaminase (PBGD) mutants of acute intermittent porphyria.
Pseudoexon activation in the HMBS gene as a cause of the nonerythroid form of acute intermittent porphyria.
Purple pigments: The pathophysiology of acute porphyric neuropathy.
R325X mutation in exon 15 of the hydroxymethylbilane synthase gene identified in two Danish families with acute intermittent porphyria.
Rat kidney porphobilinogen deaminase kinetics. Detection of enzyme-substrate complexes.
Recent advances in the epidemiology and genetics of acute intermittent porphyria.
Recurrence risk estimation of acute intermittent porphyria based on analysis of porphobilinogen deaminase activity: a Bayesian approach.
Recurrent attacks of acute hepatic porphyria: major role of the chronic inflammatory response in the liver.
Recurrent Seizures in an Adolescent Female-A Daunting Puzzle.
Red blood cell porphobilinogen deaminase in the evaluation of acute intermittent porphyria.
Red cell uroporphyrinogen I synthetase in acute intermittent porphyria.
Reference values of 5-aminolevulinate dehydrase and porphobilinogen deaminase in the Spanish population from Madrid.
Renal transplantation in a case of acute intermittent porphyria.
Residual activity of human porphobilinogen deaminase with R167Q or R167W mutations: an explanation for survival of homozygous and compound heterozygous acute intermittent porphyrics.
Reversible MRI findings in a case of acute intermittent porphyria with a novel mutation in the porphobilinogen deaminase gene.
Reversible splenial lesion syndrome (RESLES) due to acute intermittent porphyria with a novel mutation in the hydroxymethylbilane synthase gene.
RFLP analysis of three different types of acute intermittent porphyria.
Role of two nutritional hepatic markers (insulin-like growth factor 1 and transthyretin) in the clinical assessment and follow-up of acute intermittent porphyria patients.
Safety and liver transduction efficacy of rAAV5-cohPBGD in non-human primates: A potential therapy for Acute Intermitent Porphyria.
Safety, pharmacokinetics and pharmocodynamics of recombinant human porphobilinogen deaminase in healthy subjects and asymptomatic carriers of the acute intermittent porphyria gene who have increased porphyrin precursor excretion.
Seven novel genetic mutations within the 5'UTR and the housekeeping promoter of HMBS gene responsible for the non-erythroid form of acute intermittent porphyria.
Seven Novel Mutations in Bulgarian Patients with Acute Hepatic Porphyrias (AHP).
Severe hydroxymethylbilane synthase deficiency causes depression-like behavior and mitochondrial dysfunction in a mouse model of homozygous dominant acute intermittent porphyria.
Sevoflurane: its action on heme metabolism and Phase I drug metabolizing system.
Sex differences in vascular reactivity in mesenteric arteries from a mouse model of acute intermittent porphyria.
Steady-state transcript levels of the porphobilinogen deaminase gene in patients with acute intermittent porphyria.
Structure of human porphobilinogen deaminase at 2.8 A: the molecular basis of acute intermittent porphyria.
Studies in porphyria. IV. Expression of the gene defect of acute intermittent porphyria in cultured human skin fibroblasts and amniotic cells: prenatal diagnosis of the porphyric trait.
Studies on erythrocyte porphobilinogen deaminase and uroporphyrinogen cosynthetase in porphyria cutanea tarda.
Sustained Enzymatic Correction by rAAV-Mediated Liver Gene Therapy Protects Against Induced Motor Neuropathy in Acute Porphyria Mice.
Systematically Analyzing the Pathogenic Variations for Acute Intermittent Porphyria.
Systemic Administered mRNA as Therapy for Metabolic Diseases.
Systemic messenger RNA as an etiological treatment for acute intermittent porphyria.
The activity of erythrocyte porphobilinogen deaminase in familial and sporadic forms of porphyria cutanea tarda.
The diagnosis of acute intermittent porphyria. Usefulness and limitations of the erythrocyte uroporphyrinogen I synthase assay.
The three-dimensional structures of mutants of porphobilinogen deaminase: toward an understanding of the structural basis of acute intermittent porphyria.
The tolerability of newer immunosuppressive medications in a patient with acute intermittent porphyria.
The use of rocuronium and sevoflurane in acute intermittent porphyria--a case report.
The W198X and R173W mutations in the porphobilinogen deaminase gene in acute intermittent porphyria have higher clinical penetrance than R167W. A population-based study.
Therapeutic strategies for acute intermittent porphyria.
Three splicing defects, an insertion, and two missense mutations responsible for acute intermittent porphyria.
Tissue-specific expression of porphobilinogen deaminase. Two isoenzymes from a single gene.
Tissue-specific splicing mutation in acute intermittent porphyria.
Two deletion mutations in the hydroxymethylbilane synthase gene in two unrelated Japanese patients with acute intermittent porphyria.
Two different point G to A mutations in exon 10 of the porphobilinogen deaminase gene are responsible for acute intermittent porphyria.
Two new mutations in the porphobilinogen deaminase gene and a screening method using PCR amplification of specific alleles.
Two novel mutations of the porphobilinogen deaminase gene in acute intermittent porphyria.
Updates on the diagnosis and management of the most common hereditary porphyrias: AIP and EPP.
Uroporphyrinogen synthetase in erythrocytes. Its diagnostic value in latent acute intermittent porphyria with special regard to the gene penetrance.
Validation and evaluation of two porphobilinogen deaminase activity assays for diagnosis of acute intermittent porphyria.
Variable phenotypic expression of genotypic abnormalities in the porphyrias.
Variations in erythrocyte uroporphyrinogen I synthetase activity in non porphyrias.
Variegate porphyria with coexistent decrease in porphobilinogen deaminase activity.
Vitamin D-binding protein as a biomarker of active disease in acute intermittent porphyria.
Whole Exome Sequencing Identified a Novel Heterozygous Mutation in HMBS Gene in a Chinese Patient With Acute Intermittent Porphyria With Rare Type of Mild Anemia.
[A 25-year-old patient with colonic pseudo-obstruction, hyponatremia, hypertension, and diffuse pain]
[Acute intermittent porphyria and chronic transaminase elevation]
[Acute intermittent porphyria in the puerperium].
[Acute intermittent porphyria: Long-term follow up of 35 patients].
[Acute intermittent porphyria]
[Determination of uroporphyrinogen I synthase in whole blood--a method for the diagnosis and early recognition of acute intermittent porphyria]
[Diagnosis of acute intermittent porphyria on the basis of uroporphyrinogen I synthase activity in the erythrocytes; comparison of 2 methods]
[Effect of starvation and phenobarbital on the activity of liver uroporphyrinogen synthetase]
[Enzyme deficiency of erythrocytes in human porphyria]
[Evaluation of the diagnostic usefulness of determining porphobilinogen deaminase activity in the erythrocytes in patients with acute intermittent porphyria and in carriers of the gene of this type of porphyria]
[Genetic studies of families of patients with porphyria. Determination of uroporphyrinogen I synthase in the erythrocytes]
[Molecular genetic study of acute intermittent porphyria in Russia: mutation analysis and functional polymorphism search in porphobilinogen deaminase gene]
[Normal activity of uroporphyrinogen I synthase during an attack of acute intermittent porphyria]
[Plasma and salivary markers of oxidative and carbonyl stress in patients with acute intermittent porphyria].
[The initial results of detecting mutations in the gene of the porphobilinogen deaminase enzyme in patients with acute intermittent porphyria in Russia]
[Three new mutations in the porphobilinogen deaminase gene, detected in acute intermittent porphyria patients from Russia]
[Three single nucleotide polymorphisms of porphobilinogen deaminase gene related to a Chinese patient with acute intermittent porphyria]
[Uroporphyrinogen synthase in erythrocytes in acute intermittent porphyria: new pathobiochemical aspects (author's transl)]
Porphyrias, Hepatic
"Glucose effect" and rate limiting function of uroporphyrinogen synthase on porphyrin metabolism in hepatocyte culture: relationship with human acute hepatic porphyrias.
AAV8-mediated Gene Therapy Prevents Induced Biochemical Attacks of Acute Intermittent Porphyria and Improves Neuromotor Function.
Acute hepatic porphyrias: Identification of 46 hydroxymethylbilane synthase, 11 coproporphyrinogen oxidase, and 20 protoporphyrinogen oxidase novel mutations.
Acute Intermittent Porphyria in a Man with Dual Enzyme Deficiencies.
Acute intermittent porphyria--impact of mutations found in the hydroxymethylbilane synthase gene on biochemical and enzymatic protein properties.
Acute intermittent porphyria: a test of clinical acumen.
Coexistence of hereditary coproporphyria with acute intermittent porphyria.
De Novo mutation found in the porphobilinogen deaminase gene in Slovak acute intermittent porphyria patient: molecular biochemical study.
Evidence for an ancestral founder of the common R116W mutation in the hydroxymethylbilane synthase gene in acute intermittent porphyria in The Netherlands.
Feline acute intermittent porphyria: a phenocopy masquerading as an erythropoietic porphyria due to dominant and recessive hydroxymethylbilane synthase mutations.
Identification and characterization of HMBS gene mutations in Spanish patients with acute intermittent porphyria.
Identification and characterization of hydroxymethylbilane synthase mutations causing acute intermittent porphyria: evidence for an ancestral founder of the common G111R mutation.
International Porphyria Molecular Diagnostic Collaborative: an evidence-based database of verified pathogenic and benign variants for the porphyrias.
Pilot study of mitochondrial bioenergetics in subjects with acute porphyrias.
Porphobilinogen deaminase deficiency in mice causes a neuropathy resembling that of human hepatic porphyria.
Porphobilinogen deaminase gene in African and Afro-Caribbean ethnic groups: mutations causing acute intermittent porphyria and specific intragenic polymorphisms.
Relationships between acute hepatic porphyrias due to genetic variability of primary enzyme defects and limiting function of uroporphyrinogen synthase.
Posterior Leukoencephalopathy Syndrome
A novel heterozygous mutation in the HMBS gene in a patient with acute intermittent porphyria and posterior reversible encephalopathy syndrome.
Protein-Energy Malnutrition
Influence of protein calorie malnutrition and fasting on the activities of delta-aminolevulinic acid dehydratase and porphobilinogen deaminase in rats.
Protoporphyria, Erythropoietic
Protoporphyrinaemia and decreased activities of 5-aminolevulinic acid dehydrase and uroporphyrinogen I synthetase in erythrocytes of a Vitamin B6-deficient epileptic boy given valproic acid and carbamazepine.
protoporphyrin ferrochelatase deficiency
Elucidation of the mechanism of mitochondrial iron loading in Friedreich's ataxia by analysis of a mouse mutant.
Renal Insufficiency
Emerging therapies for acute intermittent porphyria.
Renal failure affects the enzymatic activities of the three first steps in hepatic heme biosynthesis in the acute intermittent porphyria mouse.
Rhabdomyolysis
A novel 19-bp deletion of exon 15 in the HMBS gene causing acute intermittent porphyria associating with rhabdomyolysis during an acute attack.
Sarcoma
Identification and Validation of Housekeeping Genes for Gene Expression Analysis of Cancer Stem Cells.
Squamous Cell Carcinoma of Head and Neck
Reference gene selection for head and neck squamous cell carcinoma gene expression studies.
Starvation
[Effect of starvation and phenobarbital on the activity of liver uroporphyrinogen synthetase]
Stroke
Increased cerebral expressions of MMPs, CLDN5, OCLN, ZO1 and AQPs are associated with brain edema following fatal heat stroke.
Tachycardia
Acute intermittent porphyria: A case report
Thyroid Cancer, Papillary
Validation of Reference Genes for Normalization of Relative qRT-PCR Studies in Papillary Thyroid Carcinoma.
Tuberculosis
Time-resolved and static-ensemble structural chemistry of hydroxymethylbilane synthase.
Urinary Bladder Neoplasms
Expression of ferrochelatase has a strong correlation in protoporphyrin IX accumulation with photodynamic detection of bladder cancer.
Identification and validation of suitable endogenous reference genes for gene expression studies of human bladder cancer.
Selection of endogenous control genes for normalising gene expression data derived from formalin-fixed paraffin-embedded tumour tissue.
uroporphyrinogen decarboxylase deficiency
Dual porphyria in double heterozygotes with porphobilinogen deaminase and uroporphyrinogen decarboxylase deficiencies.
Virus Diseases
Alginate microencapsulated human hepatocytes for the treatment of acute liver failure in children.
Endogenous gene selection for relative quantification PCR and IL6 transcript levels in the PBMC's of severe and non-severe dengue cases.
Erythrocyte uroporphyrinogen synthase activity as a possible diagnostic aid in the diagnosis of lymphoproliferative diseases.
Wilms Tumor
Examination of Stability of Bone Marrow Blood RNA in the PAXgene Tube.